Cas:81565-19-7 3-Chloro-4-trifluoromethylpyridine manufacturer & supplier

Chemical Name:3-Chloro-4-trifluoromethylpyridine

CAS.NO:81565-19-7

Synonyms:3-Chloro-4-trifluoromethyl pyridine;Pyridine, 3-chloro-4-(trifluoromethyl)-;3-Chloro-4-(trifluoromethyl)pyridine;3-Chloro-4-trifluoromethylpyridine;MFCD07368053

Molecular Formula:C₆H₃ClF₃N

Molecular Weight:181.543

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:180.9±35.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.447

PSA:12.89000

Exact Mass:180.990616

LogP:2.28

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-Chloro-4-trifluoromethyl pyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD07368053 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Chloro-4-(trifluoromethyl)pyridine Use and application,3-Chloro-4-trifluoromethylpyridine technical grade,usp/ep/jp grade.

Related News: Other possible health risks of PFAS include kidney cancer, testicular cancer and high blood pressure, the researchers added. 3-Chloro-4-trifluoromethylpyridine manufacturer Immediately thereafter, the iLet begins controlling blood-sugar levels automatically, without requiring the user to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections. 3-Chloro-4-trifluoromethylpyridine supplier It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion. 3-Chloro-4-trifluoromethylpyridine vendor It is estimated that the size of China’s CMO market has reached about USD 5 billion. With the implementation and further implementation of the MAH system (the core is to separate drug marketing authorization from drug production authorization) in China, it is expected to promote the outbreak of the domestic drug CMO industry. It will grow at a rate of 20% to 30%, of which patented APIs occupy a larger proportion. 3-Chloro-4-trifluoromethylpyridine factory Immediately thereafter, the iLet begins controlling blood-sugar levels automatically, without requiring the user to count carbohydrates, set insulin delivery rates, or deliver bolus insulin for meals or corrections.